Geneos Wealth Management’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.69M | Sell |
5,365
-250
| -4% | -$120K | 0.05% | 330 |
|
|
2026
Q1 | $2.76M | Buy |
5,615
+636
| +13% | +$345K | 0.06% | 312 |
|
|
2025
Q4 | $2.88M | Sell |
4,979
-35
| -0.7% | -$19.8K | 0.07% | 297 |
|
|
2025
Q3 | $2.43M | Sell |
5,014
-2,003
| -29% | -$932K | 0.06% | 316 |
|
|
2025
Q2 | $2.85M | Buy |
7,017
+2,351
| +50% | +$983K | 0.07% | 305 |
|
|
2025
Q1 | $2.32M | Buy |
4,666
+415
| +10% | +$225K | 0.08% | 285 |
|
|
2024
Q4 | $2.21M | Sell |
4,251
-142
| -3% | -$78.1K | 0.08% | 278 |
|
|
2024
Q3 | $2.72M | Buy |
4,393
+1,764
| +67% | +$1.04M | 0.1% | 231 |
|
|
2024
Q2 | $1.45M | Buy |
2,629
+157
| +6% | +$89.9K | 0.06% | 298 |
|
|
2024
Q1 | $1.44M | Buy |
2,472
+12
| +0.5% | +$6.73K | 0.07% | 295 |
|
|
2023
Q4 | $1.31M | Sell |
2,460
-61
| -2% | -$29.5K | 0.06% | 284 |
|
|
2023
Q3 | $1.28M | Buy |
2,521
+85
| +3% | +$45.3K | 0.07% | 275 |
|
|
2023
Q2 | $1.27M | Buy |
2,436
+61
| +3% | +$32.9K | 0.07% | 274 |
|
|
2023
Q1 | $1.37M | Sell |
2,375
-49
| -2% | -$27.6K | 0.08% | 253 |
|
|
2022
Q4 | $1.33M | Sell |
2,424
-110
| -4% | -$58.3K | 0.08% | 228 |
|
|
2022
Q3 | $1.28M | Sell |
2,534
-211
| -8% | -$118K | 0.09% | 214 |
|
|
2022
Q2 | $1.5M | Sell |
2,745
-47
| -2% | -$25.9K | 0.07% | 246 |
|
|
2022
Q1 | $1.65M | Buy |
2,792
+65
| +2% | +$37.3K | 0.07% | 256 |
|
|
2021
Q4 | $1.82M | Buy |
2,727
+58
| +2% | +$36.2K | 0.07% | 267 |
|
|
2021
Q3 | $1.53M | Buy |
2,669
+9
| +0.3% | +$4.94K | 0.06% | 292 |
|
|
2021
Q2 | $1.36M | Sell |
2,660
-914
| -26% | -$431K | 0.05% | 296 |
|
|
2021
Q1 | $1.68M | Buy |
3,574
+67
| +2% | +$32K | 0.05% | 316 |
|
|
2020
Q4 | $1.22M | Buy |
3,507
+876
| +33% | +$411K | 0.05% | 305 |
|
|
2020
Q3 | $1.11M | Sell |
2,631
-320
| -11% | -$132K | 0.06% | 272 |
|
|
2020
Q2 | $1.03M | Sell |
2,951
-37
| -1% | -$12.4K | 0.06% | 279 |
|
|
2020
Q1 | $819K | Sell |
2,988
-185
| -6% | -$58.3K | 0.06% | 280 |
|
|
2019
Q4 | $1.04M | Buy |
3,173
+185
| +6% | +$56.1K | 0.06% | 292 |
|
|
2019
Q3 | $858K | Hold |
2,988
| – | – | 0.05% | 301 |
|
|
2019
Q2 | $877K | Sell |
2,988
-14
| -0.5% | -$3.86K | 0.05% | 301 |
|
|
2019
Q1 | $821K | Buy |
3,002
+2,331
| +347% | +$580K | 0.05% | 305 |
|
|
2018
Q4 | $149K | Sell |
671
-1
| -0.1% | -$235 | 0.01% | 695 |
|
|
2018
Q3 | $164K | Buy |
672
+50
| +8% | +$11.5K | 0.01% | 712 |
|
|
2018
Q2 | $128K | Sell |
622
-37
| -6% | -$7.85K | 0.01% | 707 |
|
|
2018
Q1 | $136K | Hold |
659
| – | – | 0.01% | 650 |
|
|
2017
Q4 | $125K | Hold |
659
| – | – | 0.01% | 679 |
|
|
2017
Q3 | $124K | Hold |
659
| – | – | 0.01% | 643 |
|
|
2017
Q2 | $114K | Sell |
659
-7
| -1% | -$1.18K | 0.01% | 647 |
|
|
2017
Q1 | $102K | Sell |
666
-9
| -1% | -$1.38K | 0.01% | 656 |
|
|
2016
Q4 | $95K | Sell |
675
-12
| -2% | -$1.77K | 0.01% | 628 |
|
|
2016
Q3 | $109K | Buy |
687
+16
| +2% | +$2.47K | 0.01% | 580 |
|
|
2016
Q2 | $100K | Sell |
671
-77
| -10% | -$11.4K | 0.01% | 588 |
|
|
2016
Q1 | $106K | Buy |
+748
| New | +$100K | 0.02% | 564 |
|
Other funds holding TMO
Geneos Wealth Management's TMO Position: Q2 2026 in Review
Geneos Wealth Management reduced its Thermo Fisher Scientific (TMO) stake by 4.5% in Q2 2026, selling an estimated $120K and leaving 5,365 shares worth $2.69M. The position accounts for 0.05% of the portfolio, ranked #330.
Geneos Wealth Management first reported a position in TMO in Q1 2016 and has held it in 42 quarters since. The position peaked at $2.88M in Q4 2025. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- Geneos Wealth Management held 5,365 shares of Thermo Fisher Scientific worth $2.69M as of Q2 2026.
- Geneos Wealth Management sold 250 Thermo Fisher Scientific shares in Q2 2026, an estimated $120K.
- Thermo Fisher Scientific made up 0.05% of Geneos Wealth Management's portfolio in Q2 2026, its #330 holding.
- Geneos Wealth Management first reported a position in Thermo Fisher Scientific in Q1 2016 and has held it in 42 quarters since.
- Geneos Wealth Management's Thermo Fisher Scientific position peaked at $2.88M in Q4 2025.
- 2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on Geneos Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.